Excelera ® Specialty Pharmacy Network Announces Access to Breast...

The U.S. Food and Drug Administration approved NERLYNX (neratinib) for the extended adjuvant treatment of early-stage, HER2-positive breast cancer in July 2017...(PRWeb July 17, 2018)Read the full story at https://www.prweb.com/releases/2018/06/prweb15575484.htm
Source: PRWeb: Medical Pharmaceuticals - Category: Pharmaceuticals Source Type: news